Research to support optimization of prescription drug monitoring programs

被引:9
作者
Doyle, Sheri [1 ,2 ]
Leichtling, Gillian
Hildebran, Christi
Reilly, Cynthia
机构
[1] Brandeis Univ, Pew Charitable Trusts, HealthInsight Oregon,Bur Justice Assistance, Prescript Drug Monitoring Program Ctr Excellence, 901 E St NW,10th Fl, Washington, DC 20004 USA
[2] Johns Hopkins Ctr Drug Safety & Effectiveness, 901 E St NW,10th Fl, Washington, DC 20004 USA
关键词
D O I
10.1002/pds.4300
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeResearch is needed to evaluate the impact of prescription drug monitoring programs (PDMPs). This paper describes research priorities for PDMPs that were initially discussed at a 2015 meeting of PDMP administrators, researchers, public health officials, and other stakeholders. MethodsMeeting participants defined the current landscape of PDMP research and identified research gaps. Research priorities were grouped by theme. ResultsPrescription drug monitoring program research priorities were identified for 3 key areas: individual patient health outcomes, prescriber use and decision making, and population-level outcomes. Research areas for individual patient outcomes include examining drug-use thresholds that best predict risk for overdose or substance use disorder and unintended consequences of PDMP use. Proposed research on prescriber PDMP use include evaluating how enhancements to the content and format of PDMP reports informs clinical decision making and optimal clinician actions in response to a concerning PDMP report. Finally, research topics related to population-level outcomes include measuring the impact of PDMP policies on the incidence of substance misuse and harms and assessing the return on investment for these databases. ConclusionsThe clinical, public health, and economic impacts of PDMPs must be evaluated, using both quantitative and qualitative methods. In addition to assessing patient outcomes, qualitative research should examine how clinicians use and interpret PDMP information. Research should also examine the impact of PDMP features and policies on prescriber utilization. Comparative analyses across states with differing PDMP policies should be conducted to inform best practices.
引用
收藏
页码:1425 / 1427
页数:3
相关论文
共 6 条
[1]  
[Anonymous], 2015, EV PDMP RES FOR ID P
[2]  
Finklea K, 2014, PRESCRIPTION DRUG MO, P8
[3]  
Fleming Marc L, 2013, J Pain Palliat Care Pharmacother, V27, P136, DOI 10.3109/15360288.2013.788598
[4]   Who Uses a Prescription Drug Monitoring Program and How? Insights From a Statewide Survey of Oregon Clinicians [J].
Irvine, Jessica M. ;
Hallvik, Sara E. ;
Hildebran, Christi ;
Marino, Miguel ;
Beran, Todd ;
Deyo, Richard A. .
JOURNAL OF PAIN, 2014, 15 (07) :747-755
[5]   Most Primary Care Physicians Are Aware Of Prescription Drug Monitoring Programs, But Many Find The Data Difficult To Access [J].
Rutkow, Lainie ;
Turner, Lydia ;
Lucas, Eleanor ;
Hwang, Catherine ;
Alexander, G. Caleb .
HEALTH AFFAIRS, 2015, 34 (03) :484-492
[6]   How, Why, and for Whom Do Emergency Medicine Providers Use Prescription Drug Monitoring Programs? [J].
Smith, Robert J. ;
Kilaru, Austin S. ;
Perrone, Jeanmarie ;
Paciotti, Breah ;
Barg, Frances K. ;
Gadsden, Sarah M. ;
Meisel, Zachary F. .
PAIN MEDICINE, 2015, 16 (06) :1122-1131